Eight Roads China announces Partner promotion

Eight Roads is pleased to announce that it has promoted Dr. Lei Shi to Partner in its China Ventures team, leading and overseeing the firm’s Medical Device, Diagnostics & Life Science Tools investments as it continues to develop a comprehensive healthcare ecosystem across the industry value chain in China.  

With more than 25 years of investment experience in China, Eight Roads has been recognized as a platform that brings sector expertise, diverse and complementary background, and an entrepreneurial spirit focused on adding value to the businesses we support. As a growing team with our own culture, set of values and beliefs, Eight Roads consciously celebrate diversity, encourage collaboration, and empower our team to work and excel together.

 “We are pleased to welcome Dr. Shi Lei to our healthcare leadership team and celebrate his commitment to the values of our organization. Dr. Lei reflects the rich depth in medtech of our global footprint and the strength of the diversity in talent that powers our thematic healthcare investment model which in turn delivers on our commitment to our portfolio companies and their founders” said Jarlon Tsang, Managing Partner and Head of China at Eight Roads.

Dr. Lei joined Eight Roads in 2016 as Director in Portfolio Management and transferred to the Healthcare investment team as Vice President in 2018. Since then, he has been leading the Med Tech team to invest in domestic leading platforms and build first movers in China for proven innovations. Lei is responsible for several Eight Roads portfolio companies, including LenoMed, Nanos Medical, RedPine Medical, b-ONE Orthopedics,  OrigynMED, BioBiggen, ingeDx and SonoSemi, etc.

Prior to joining Eight Roads, Dr. Lei worked for Baxter International as the Head of Strategic Initiatives for Greater China where he led the team in both organic and inorganic growth initiatives of the company. Lei holds a Ph.D. in Neuroscience and M.S. in Statistics from University of California-Berkeley, a M.S. in Mathematics and M.S. in Communications Engineering from Technical University of Munich, and a Bachelor of Electrical Engineering from Shanghai Tongji University.

At Eight Roads, we believe in bringing positive change to society while building extraordinary businesses. In the healthcare industry, we strive to develop a complete ecosystem, beneficial to patients, doctors, hospital operators and the entire community. To date, Eight Roads has invested in over 60 healthcare companies in China, sitting across therapeutics (WuXi Apptec, Innovent Biologics, Adagene, Insilico Medicine, Semma Therapeutics, Hua Medicine, Westlake Therapeutics, etc.), Med Tech (EyeBright, Cytek Bioscience, Nanos Medical, b-ONE, LenoMed, RedPine, etc.), healthcare services (DeltaHealth, BangEr, Gushengtang, Arion, OST, KnowYourself, etc.) and digital health (Medbanks, MediTrust, FuCunBao, Haici, Gyenno Science, etc.) sectors. In 2021, Eight Roads launched the latest $400M China Healthcare Fund to continue partnering with innovative and transformational healthcare and life science companies in China.

Globally, Eight Roads has backed more than 210 companies in healthcare, of which 43 have completed an initial public offering (IPO) on a stock exchange in mainland China, Hong Kong or the US, including WuXi Apptec, Adagene, Beam Therapeutics, Denali Therapeutics, EyeBright, Gushengtang, Innovent, Laurus Labs, OcuMension, etc.